Announcement

Collapse
No announcement yet.

EU approves lemtrada (campath)

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    EU approves lemtrada (campath)

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 17, 2013--
    Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY) announced today that the European Commission has granted marketing authorization for Lemtrada(TM). This follows the August 30th approval of Aubagio(R). The company intends to begin launching both products in the EU soon.

    "The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients," said Genzyme CEO and President, David Meeker, M.D. "This is particularly exciting as the EU approval is the first for Lemtrada globally. We look forward to making these unique therapies available to MS patients very soon."

    Lemtrada is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. Lemtrada 12 mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtrada is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later.
Working...
X